| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
YC-001 (0-100 µM) exhibits an efficacy of 150–310% and a potency activity of 8.7 µM[1]. P23H opsin mutants exhibit improved glycosylation properties when treated with YC-001 (0.5, 1, 5, 10, 20, 40 µM) [1]. Rod photoreceptor proteins are reversibly bound by YC-001 (0,-1.5 µM), with an EC50 of 0.98 µM[1]. In NIH3T3 cells, YC-001 (0.313, 0.625, 1.25, 2.5, 5, 10, 20, 80 µM) raises cAMP levels in a dose-dependent way [1].
|
|---|---|
| ln Vivo |
Bright light-induced retinal degeneration in Abca4−/−Rdh8−/− mice is prevented by intraperitoneal injection of YC-001 (50, 200 mg/kg) [1]. After systemic administration, mice receive an intraperitoneal injection of YC-001 (200 mg/kg), which enters their eyes but does not stay there for very long [1]. YC-001 (intraperitoneal injection, 100 mg/kg, 200 mg/kg; once daily for 24 days) exhibited almost no acute toxicity [
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: NIH3T3 Cell Tested Concentrations: 0.5, 1, 5, 10, 20, 40 µM Incubation Duration: Experimental Results: Improved glycosylation profile of P23H opsin. |
| Animal Protocol |
Animal/Disease Models: 6weeks old Abca4 −/−Rdh8−/− mice [1]
Doses: 50, 200mg/kg Route of Administration: IP Experimental Results: Protection of Abca4−/−Rdh8−/− mice from strong light-induced Retinal degeneration. Animal/Disease Models: C57BL/6 mice [1] Doses: 200 mg/kg Route of Administration: IP Experimental Results: After systemic administration, it enters the eyes of mice but does not remain for a long time. Animal/Disease Models: C57BL/6 mice[1] Doses: 100 mg/kg, 200 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 24 days Experimental Results: No acute toxicity was shown. |
| References |
| Molecular Formula |
C12H7CLO2S2
|
|---|---|
| Molecular Weight |
282.765779733658
|
| Exact Mass |
281.957
|
| CAS # |
748778-73-6
|
| PubChem CID |
2377702
|
| Appearance |
White to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
494.2±45.0 °C at 760 mmHg
|
| Flash Point |
252.7±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.686
|
| LogP |
3.35
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
370
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RCLLWMPOHNZNAO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H7ClO2S2/c13-10-4-3-8(17-10)7-6-15-12(14)11(7)9-2-1-5-16-9/h1-5H,6H2
|
| Chemical Name |
3-(5-chlorothiophen-2-yl)-4-thiophen-2-yl-2H-furan-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~353.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5364 mL | 17.6822 mL | 35.3644 mL | |
| 5 mM | 0.7073 mL | 3.5364 mL | 7.0729 mL | |
| 10 mM | 0.3536 mL | 1.7682 mL | 3.5364 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
